MARKET

BYSI

BYSI

BeyondSpring
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.66
-0.08
-0.68%
After Hours 16:41 08/14 EDT
OPEN
11.88
PREV CLOSE
11.74
HIGH
12.07
LOW
11.42
VOLUME
46.14K
TURNOVER
--
52 WEEK HIGH
23.00
52 WEEK LOW
9.38
MARKET CAP
351.06M
P/E (TTM)
-6.5242
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BYSI stock price target is 37.25 with a high estimate of 46.00 and a low estimate of 25.00.

EPS

BYSI News

More
BeyondSpring Initiates Expanded Access Program With Plinabulin For Patients Suffering From CIN In The U.S.
Benzinga · 3d ago
BeyondSpring 13D Shows Decheng Capital China Life Sciences USD Fund II Holds 5.7% Active Stake In Co.
Benzinga · 07/27 21:22
New Stem Cell-Based Application for BeyondSprings Plinabulin Presented at ISSCR Annual Meeting
GlobeNewswire · 06/30 12:00
BeyondSpring Highlights Presentation Of Plinabulin Data
Data Presented Shows Plinabulin Mobilizes Bone Marrow CD34+ Progenitor Cells through a Mechanism of Action Independent from G-CSFs and CXCR4  NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the
Benzinga · 06/30 11:10
BeyondSpring (BYSI) Catches Eye: Stock Jumps 10.9%
BeyondSpring (BYSI) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Zacks · 06/24 04:02
New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSprings Plinabulin
GlobeNewswire · 06/23 13:00
BeyondSpring Highlights Presentation Of Triple I/O Combination Therapy With Plinabulin
Research Presented at 2020 AACR Virtual Annual Meeting   The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal
Benzinga · 06/23 12:06
Why BeyondSpring Is Plunging Today
MotleyFool.com · 06/19 16:59

Industry

Biotechnology & Medical Research
-0.56%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About BYSI

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Company’s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived small-molecule with a range of biological activities. Plinabulin targets cells in the tumor vasculature resulting in selective anti-tumor activity. Plinabulin has also demonstrated a range of immuno-stimulatory effects, including stimulating the maturation of dendritic cells, increasing cytokine secretion, downregulating inhibitory T-cells, and stimulating tumor-antigen-specific T-cell activation.
More

Webull offers kinds of Beyondspring Inc stock information, including NASDAQ:BYSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BYSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BYSI stock methods without spending real money on the virtual paper trading platform.